Sign in

Brad Canino

Director and Equity Research Analyst at Stifel Financial Corp.

Brad Canino is a Director and Equity Research Analyst at Stifel Financial Corp., specializing in biotechnology sector analysis with a primary focus on oncology companies. He covers around 35 biopharma stocks—including Blueprint Medicines—and has a performance track record with a current 25% success rate and an average return of -11.5% according to TipRanks. Canino began his equity research career at UBS, later serving as Vice President at SVB Leerink and as a Senior Analyst at Credit Suisse before joining Stifel in 2021; he also brings auditing experience from PwC. He holds a B.S. in Accounting and an MBA from Le Moyne College, is a licensed CPA, and contributes to Stifel’s coverage of over 250 healthcare and biotechnology companies.

Brad Canino's questions to Summit Therapeutics (SMMT) leadership

Brad Canino's questions to Summit Therapeutics (SMMT) leadership • Q3 2025

Question

Brad Canino questioned the strategic rationale behind submitting the HARMONi study BLA first, given potential OS review issues, instead of waiting for the HARMONi-3 data (PFS and OS) expected in the second half of 2026. He also asked for qualitative details on the undisclosed in-house colorectal phase III data, its extent, and when it might be presented.

Answer

Urte Gayko, Chief Regulatory Quality and Safety Officer, explained that each indication has its own submission, and the HARMONi package is ready, representing a timely opportunity. Bob Duggan, Chairman of the Board and Co-CEO, provided historical context on FDA's support for the HARMONi trial. Dave Gancarz, Chief Business and Strategy Officer, described the colorectal data, mentioning previous ESMO 2024 presentations, expansion to U.S. patients with FOLFOX, and confidence in the regimen, while noting Akeso is also running a phase III.

Ask Fintool Equity Research AI

Brad Canino's questions to Kyverna Therapeutics (KYTX) leadership

Brad Canino's questions to Kyverna Therapeutics (KYTX) leadership • Q3 2024

Question

Brad Canino asked about the clinical development plan for the STAT6 degrader, questioning which TH2 disease would be best to demonstrate a Dupilumab-like effect and whether biomarker data alone would suffice for initial patient studies.

Answer

Founder, President, and CEO Nellie Monofi explained that after the Phase 1 study, a small, rapid biomarker study in atopic dermatitis (AD) patients could quickly validate the drug's impact, leveraging the well-defined biomarker signature of Dupilumab. This could accelerate the program's progression into larger pivotal studies.

Ask Fintool Equity Research AI

Brad Canino's questions to Kyverna Therapeutics (KYTX) leadership • Q2 2024

Question

Brad Canino from Stifel asked about the company's confidence in TIC2 as a target for IBD given external news, and also questioned how Chimera balances its discovery efforts with its advancing clinical pipeline.

Answer

CMO Jared Golub expressed confidence in TIC2 for IBD, noting their degrader's selectivity spares IL-10 signaling, a key advantage. CEO Nello Manalfi added that discovery efforts remain robust, focused on validated pathways and difficult-to-drug targets in immunology, with the ambition to build the industry's leading oral immunology pipeline.

Ask Fintool Equity Research AI

Brad Canino's questions to Blueprint Medicines (BPMC) leadership

Brad Canino's questions to Blueprint Medicines (BPMC) leadership • Q2 2024

Question

Asked about the evolution of patient eligibility for AYVAKIT as physicians gain experience, the profile of patients starting therapy at experienced practices, and the long-term vision for the eligible patient population.

Answer

Physicians with experience are broadening their view of eligible patients beyond the most severe cases. This trend is supported by claims data. The company believes almost all SM patients are eligible under the broad label and that the true prevalence of the disease may be underestimated, suggesting the peak opportunity could be even larger than currently projected.

Ask Fintool Equity Research AI